Back to search

National and Kapodistrian University of Athens

Μεταβολές λιπιδαιμικών δεικτών σε ασθενείς που λαμβάνουν ορμονική θεραπεία για κακοήθεις νεοπλασίες του μαστού

Abstract

dc:description

Background and aim: Hormonal modulation therapy is an important component of hormone receptorpositive breast cancer treatment. However, the type and duration of hormonal therapies have distinct effects on lipid profile parameters and cardiovascular disease risk. This study aimed to investigate the impact of tamoxifen and aromatase inhibitors (AIs) on lipid profiles and high-density lipoprotein (HDL) subfractions in women with breast cancer. Materials and methods: In this retrospective observational study, 100 women were included (50 healthy controls and 50 patients with histologically confirmed breast cancer). Among breast cancer patients, 25 were premenopausal receiving tamoxifen treatment, and 25 were postmenopausal receiving AI therapy, based on routine clinical practice. Lipid parameters were assessed at baseline and following six months of treatment in all participants. Premenopausal patients received tamoxifen, while postmenopausal patients were treated with AIs. Serum total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), HDL cholesterol, and HDL subfractions (HDL-2 and HDL-3) were analyzed. Results: In the tamoxifen-treated premenopausal cohort, total cholesterol decreased by 8.48% and LDL-C by 15.94%, with redistribution toward larger HDL particles, reflected by an increase in HDL-2 of 21.1% and a decrease in HDL-3 of 12.06% (all p<0.001) In the postmenopausal aromatase inhibitor cohort, a mixed lipid pattern was observed, with increases in total cholesterol (+3.38%) and LDL-C (+7.02%), decreases in HDL-C (-1.56%) and HDL-2 (-20.75%), an increase in HDL-3 (+8.69%), and a decrease in triglycerides (-10.95%) (all p<0.001). Direct comparison of change scores between cohorts showed significant differences for all examined lipid parameters (all p<0.001). Conclusion: Distinct six-month trajectories in lipid profile parameters and HDL subfractions were observed between premenopausal women receiving tamoxifen and postmenopausal women receiving aromatase inhibitors. These findings likely reflect the combined influence of endocrine therapy and underlying menopausal physiology and should not be interpreted as a direct causal head-to-head comparison of isolated drug effects.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Nikolakopoulou, Anastasia
  • Νικολακοπούλου, Αναστασία

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/62197

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Nikolakopoulou, Anastasia; Νικολακοπούλου, Αναστασία. Μεταβολές λιπιδαιμικών δεικτών σε ασθενείς που λαμβάνουν ορμονική θεραπεία για κακοήθεις νεοπλασίες του μαστού. National and Kapodistrian University of Athens, 2026. http://hdl.handle.net/10442/hedi/62197